Free Trial
NASDAQ:EQ

Equillium Q2 2024 Earnings Report

Equillium logo
$1.91 -0.04 (-2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.87 -0.04 (-2.15%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
$13.85 million
Expected Revenue
$8.15 million
Beat/Miss
Beat by +$5.70 million
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Equillium's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Tuesday, November 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Equillium Earnings Headlines

Financial Review: Equillium (NASDAQ:EQ) and Imunon (NASDAQ:IMNN)
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
Equillium Secures $30 Million in Private Placement
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

View Equillium Profile

More Earnings Resources from MarketBeat